Technical Paper on Immunotherapy for Cancers vs Cancer Vaccines

Immune Checkpoint Inhibitors Versus Cancer Vaccines:

Mechanistic Distinctions, Immunological Foundations, and Implications for Preventive Oncology

Lim JB¹ & Sage P²
¹Independent Medical Scholar / Researcher
²Department of Theoretical Immunology

 

Abstract

Cancer immunotherapy has transformed modern oncology by harnessing endogenous immune mechanisms to eliminate malignant cells. Among its most successful modalities are immune checkpoint inhibitors (ICIs), including programmed death-1 (PD-1) pathway blockers such as Pembrolizumab. Concurrently, therapeutic cancer vaccines aim to induce tumour-specific immune responses through antigen-directed priming. Although frequently grouped under the umbrella of immunotherapy, these modalities differ fundamentally in mechanism, immunological impact, and suitability for preventive applications. This review examines the biological basis of immune checkpoint inhibition and cancer vaccination, emphasizing mechanisms of central and peripheral tolerance. We analyse why checkpoint inhibitors, despite their therapeutic efficacy, are biologically unsuitable for use in healthy individuals as preventive agents. The distinction between immune amplification and immune education is critical for guiding future strategies in immuno-prevention and maintaining the balance between anti-tumour immunity and self-tolerance.

Executive Summary

Cancer immunotherapy has fundamentally transformed modern oncology by shifting treatment strategies from direct cytotoxic destruction of tumour cells to modulation of the host immune system. Among the most impactful advances are immune checkpoint inhibitors (ICIs), particularly programmed death-1 (PD-1) pathway blockers such as Pembrolizumab. These agents restore anti-tumour T-cell activity by disrupting inhibitory signalling pathways that normally maintain immune tolerance.

However, checkpoint inhibition and cancer vaccination represent mechanistically distinct immunological strategies. Checkpoint inhibitors amplify immune activity by releasing peripheral inhibitory control mechanisms such as PD-1 and CTLA-4. In contrast, cancer vaccines aim to induce antigen-specific immune responses through targeted priming and immunological memory formation.

This distinction carries profound implications. While checkpoint inhibitors have demonstrated significant survival benefits across multiple malignancies, their mechanism inherently disrupts immune tolerance and may precipitate immune-related adverse events, including organ-specific autoimmune disorders. The same biological mechanism that enables tumour eradication also increases the risk of collateral tissue damage.

A question a medical specialist colleague asked whether checkpoint inhibitors could be used prophylactically in healthy individuals to stimulate anti-cancer immunity raises critical immunological and ethical concerns. Unlike vaccines, checkpoint inhibitors do not introduce tumour-specific antigens or enhance immune precision. Rather, they remove regulatory restraints that are essential for preventing autoimmunity. In the absence of active tumour antigen stimulation, broad immune activation may lead to loss of peripheral tolerance without conferring meaningful protective benefit.

Preventive oncology requires enhancement of immune surveillance while preserving immunological equilibrium. Based on current mechanistic understanding, immune checkpoint blockade is biologically unsuitable as a generalized preventive strategy in healthy populations. The contrast between immune amplification and immune education underscores the need for precision in future immuno-preventive research.

Keywords

Cancer immunotherapy; immune checkpoint inhibitors; PD-1; pembrolizumab; cancer vaccines; immune tolerance; autoimmunity; immuno-prevention

 

1. Introduction

The development of cancer immunotherapy represents a paradigm shift in oncology. Rather than directly targeting tumour cells through cytotoxic agents, immunotherapy modulates host immune responses to enhance tumour recognition and destruction. Major modalities include immune checkpoint inhibitors (ICIs), adoptive cell therapies, monoclonal antibodies, antibody-drug conjugates, oncolytic viral therapy, therapeutic cancer vaccines, and cytokine-based immunomodulators.

While these approaches share the objective of enhancing anti-tumour immunity, their mechanisms differ substantially. In particular, immune checkpoint inhibitors and cancer vaccines operate at distinct regulatory levels of immune activation. This distinction becomes critically important when considering theoretical preventive applications in individuals without established malignancy.

2. Immune Checkpoint Inhibition: Mechanistic Foundations

2.1 Physiological Role of Immune Checkpoints

T-cell activation is tightly regulated by stimulatory and inhibitory signals. Two principal inhibitory pathways are cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed death-1 (PD-1).

CTLA-4 regulates early T-cell activation within secondary lymphoid organs by competing with CD28 for B7 ligands on antigen-presenting cells. PD-1, in contrast, primarily regulates T-cell activity in peripheral tissues. Upon engagement with its ligands PD-L1 or PD-L2, PD-1 signalling suppresses T-cell proliferation, cytokine production, and cytotoxic function.

These checkpoints are essential for maintaining peripheral tolerance and preventing immune-mediated tissue injury.

2.2 Tumour Immune Evasion

Many tumour cells upregulate PD-L1 expression, thereby engaging PD-1 on tumour-infiltrating lymphocytes and inducing T-cell exhaustion. This immune evasion strategy allows malignant cells to persist despite antigenic recognition.

Checkpoint inhibitors disrupt this inhibitory interaction, restoring cytotoxic T-cell function.

2.3 Clinical Application of Pembrolizumab

Pembrolizumab is a humanized monoclonal antibody targeting PD-1. By blocking PD-1 receptor engagement, it enhances T-cell-mediated tumour destruction.

It has received regulatory approval for multiple malignancies, including:

(a) Melanoma

(b) Non-small cell lung cancer

(c) Head and neck squamous cell carcinoma

(d) Triple-negative breast cancer

(e) Classical Hodgkin lymphoma

(f) Microsatellite instability-high (MSI-H)

(g) or mismatch repair-deficient tumours (tumour-agnostic approval)

Its tumour-agnostic approval marked a milestone in biomarker-driven oncology, reflecting a shift from organ-based to molecularly guided therapy.

3. Immunological Tolerance: Central and Peripheral Control

3.1 Central Tolerance

During thymic development, T cells undergo negative selection to eliminate strongly self-reactive clones. This establishes central tolerance but is not absolute.

Autoreactive T cells may escape deletion and enter peripheral circulation.

3.2 Peripheral Tolerance

Peripheral tolerance mechanisms prevent escaped autoreactive T cells from causing pathology. These include:

• Regulatory T cells (Tregs)
• Anergy induction
• Immune checkpoint pathways such as PD-1

PD-1 signaling therefore serves a physiological role in restraining self-reactivity.

 

4. Immune-Related Adverse Events and Loss of Tolerance

Checkpoint inhibition disrupts peripheral tolerance and may precipitate immune-related adverse events (irAEs). Documented toxicities include:

• Pneumonitis
• Colitis
• Hepatitis
• Nephritis
• Hypophysitis
• Thyroiditis
• Insulin-dependent diabetes mellitus
• Inflammatory arthritis

These toxicities are mechanistically linked to enhanced autoreactive T-cell activation rather than off-target drug toxicity.

In patients with advanced malignancy, this risk may be justified. In individuals without cancer, such risk would lack ethical justification.

5. Cancer Vaccines: Antigen-Specific Immune Education

Therapeutic cancer vaccines operate through antigen-specific immune priming. By introducing tumour-associated or tumour-specific neoantigens, vaccines promote:

1. Antigen uptake by dendritic cells

2. Presentation via major histocompatibility complex (MHC) molecules

3. Activation of naïve T cells

4. Clonal expansion of antigen-specific cytotoxic T lymphocytes

5. Development of immunological memory

This strategy enhances specificity rather than indiscriminate activation.

Vaccines do not remove immune checkpoints globally; instead, they provide targeted immune instruction.

6. Conceptual Distinction: Immune Amplification Versus Immune Education

Checkpoint inhibitors amplify immune intensity by removing inhibitory signalling. Cancer vaccines increase immune specificity through antigen-directed priming.

This distinction is fundamental.

Without antigenic direction, checkpoint inhibition lacks precision. In the absence of tumour antigen stimulation, broad immune activation risks self-tissue damage without therapeutic benefit.

7. Implications for Preventive Oncology

The concept of administering checkpoint inhibitors prophylactically in healthy individuals has been suggested in theoretical discussions. However, such an approach is biologically unsound for several reasons:

1. Absence of target antigen stimulation

2. Disruption of peripheral tolerance

3. Risk of irreversible autoimmune disease

4. Unfavourable risk-benefit ratio

Research into immuno-prevention is ongoing in high-risk populations (e.g., hereditary cancer syndromes or premalignant lesions), but these investigations occur under controlled clinical trial conditions. These individuals are not immunologically “healthy” controls.

Preventive strategies must preserve immune tolerance while enhancing tumour surveillance. Checkpoint blockade intrinsically compromises tolerance.

 

8. Ethical Considerations

The ethical principle of proportionality in medicine requires that therapeutic risk be justified by disease burden. In metastatic cancer, immune-related toxicities may be acceptable. In asymptomatic individuals, exposure to systemic immune dysregulation would be medically indefensible.

 

A Summary for Non-Technical Readers:

Immune checkpoint inhibitors such as Pembrolizumab have revolutionized oncology by restoring anti-tumour immunity through release of peripheral inhibitory control. Their success reflects the power of immune amplification in established malignancy.

However, checkpoint inhibitors and cancer vaccines are mechanistically distinct. Vaccines educate the immune system with antigen-specific precision. Checkpoint inhibitors remove regulatory restraints, increasing immune force but risking autoimmunity.

Preventive oncology requires strategies that enhance immune surveillance without disrupting tolerance. Based on current immunological understanding, checkpoint inhibition is unsuitable for use in healthy individuals as a preventive modality.

The immune system is a finely regulated network. Its therapeutic manipulation must respect the equilibrium between activation and tolerance upon which physiological integrity depends.

Cancer vaccines are a specific type of immunotherapy designed to teach the immune system to recognize and destroy cancer cells by targeting unique antigens. While broader immunotherapies (like checkpoint inhibitors) "release the brakes" on the immune system, vaccines actively "train" it. Vaccines generally offer higher specificity and fewer, but sometimes different, side effects compared to broader, more toxic immunotherapy.

References

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.

2. Topalian SL, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.

3. Robert C, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.

4. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.

5. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2018;18:183–194.

Immunotherapy for Cancer vs Cancer Vaccines

by: lim ju boo, alias lin ru wu (林 如 武)

This article is a simple version on the question about Immunotherapy for Cancer vs Cancer Vaccines.  It is written for ordinary medical doctors, biomedical scientists including patients with cancers who may be interested in other therapeutic options other than chemotherapies 

I shall write a much more technical version together with my research colleague later for oncologists and research scientists involved in cancer research

There are several major types of immunotherapy drugs used to treat cancer, generally classified by how they help the immune system fight cancer cells. The primary types include immune checkpoint inhibitors, adoptive cell therapies, monoclonal antibodies, treatment vaccines, and immunomodulators. 

Examples of the main types of immunotherapies.  

1. Immune Checkpoint Inhibitors. These are the most common type of immunotherapy. They block checkpoint proteins (like PD-1/PD-L1 and CTLA-4) that prevent T cells from destroying cancer cells.  

2. Adoptive Cell Therapy (T-cell transfer): This involves removing a patient's own T cells, modifying them in a lab to better recognize and kill cancer cells (such as CAR T-cell therapy), and returning them to the body.  

3. Monoclonal Antibodies (mAbs): Laboratory-made proteins designed to bind to specific targets on cancer cells, either flagging them for destruction or stopping them from growing. 

4. Antibody-Drug Conjugates (ADCs): A type of monoclonal antibody that is linked to a chemotherapy drug, allowing it to deliver the toxin directly to the cancer cell. 

5. Oncolytic Virus Therapy: Uses genetically modified viruses to infect and destroy cancer cells. 

6. Cancer Vaccines: Therapeutic vaccines that help the immune system recognize and attack specific antigens on cancer cells. 

7. Immunomodulators (Non-specific): These generally boost the immune system, including cytokines like interleukins and interferons, which help coordinate the immune response. 

As of 2023, there were over 11 FDA-approved immune checkpoint inhibitors (ICIs) covering more than 20 cancer types, with over 70 different immunotherapy drugs in clinical pipelines. 

For instance, Pembrolizumab (brand name Keytruda) is a widely used immunotherapy medication that helps the body's immune system fight cancer by blocking the PD-1/PD-L1 pathway. It is used to treat numerous advanced cancers, including melanoma, non-small cell lung cancer (NSCLC), head and neck cancer, triple-negative breast cancer, cervical cancer, and others, often as a first-line treatment.  Key uses and indications for Pembrolizumab are, 1.  melanoma treats advanced, unresectable, or metastatic melanoma, and is used to prevent recurrence after surgery. 2. Lung Cancer (NSCLC). This is used in various stages, often as first-line treatment for metastatic disease, particularly when tumours express high levels of PD-L1. 3. Head and Neck Cancer. It is used for recurrent or metastatic squamous cell carcinoma. 4. Breast Cancer: Pembrolizumab treats high-risk early-stage and metastatic triple-negative breast cancer (TNBC). 4. Gynaecological / GI Cancers. It is used to treats cervical, endometrial, oesophageal, and gastric cancers. 5. Lymphoma / Other Solid Tumours Used for classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, and

tumours with specific genetic features (MSI-H or dMMR).

Mode of action -  It is a monoclonal antibody that inhibits the PD-1 protein on immune T-cells, allowing them to better recognize and kill cancer cells. It is given intravenously (through a vein), either alone or in combination with chemotherapy. It is also  approved for a wide variety of cancer types, often regardless of the tissue of origin, provided specific biomarkers are present. Treatment decisions are made by an oncologist  based on specific biomarkers (like PD-L1 expression) and the cancer type.

When I mentioned this casually in one of my WhatsApp chat group , a specialist doctor friend in the chat group asked if we can we use pembrolizumab to stimulate the auto immunity against cancer even in healthy individual who do not have cancer instead of using cancer vaccines

My answer to him is a straight -  NO. Here are my reasons.

Using pembrolizumab (Keytruda) in healthy individuals who do not have cancer, with the goal of stimulating immunity to prevent cancer instead of using cancer vaccines, is currently not an approved or standard medical practice. While some research is exploring the concept of "immuno-prevention" for high-risk, pre-cancerous conditions, treating healthy individuals with checkpoint inhibitors like pembrolizumab poses significant, often severe, risks to overall health. This approach is not used in healthy people because of these reasons: 

1. High Risk of Severe Autoimmunity
Pembrolizumab is an "immune checkpoint inhibitor." Its mechanism involves taking the "brakes" off the immune system (blocking the PD-1 receptor) so T-cells can attack cancer cells. A healthy person’s immune system is tightly regulated to prevent it from attacking its own body. By removing these brakes, pembrolizumab causes the immune system to attack healthy cells and tissues.

Then we need to consider the side effects of immunotherapy drugs They can lead to 1. severe or life-threatening autoimmune conditions, including pneumonitis (lung inflammation), colitis (bowel inflammation), hepatitis (liver damage), nephritis (kidney damage), and damage to endocrine glands. See link:

www.keytrudahcp.com

2. "Unmasking" Autoimmunity
In healthy individuals, the PD-1/PD-L1 pathway is crucial for maintaining tolerance to self-tissues. If this pathway is blocked, the immune system may attack organs, resulting in autoimmune diseases like Type 1 diabetes, thyroid problems, or severe arthritis.

3. Different Mechanisms: Vaccines vs. Inhibitors
Cancer Vaccines: These are designed to teach the immune system to recognize specific, foreign-looking antigens on cancer cells, providing a targeted response.
Pembrolizumab: This is a broad activator of T-cells. It does not teach the immune system to recognize cancer; it simply stops the immune system from stopping itself. If there is no cancer present, it has no specific target and primarily attacks healthy tissue.

4. Current Research on Immuno-prevention
Researchers are exploring "immuno-prevention" in very specific, high-risk scenarios, such as in patients with lung nodules that have begun to change but are not yet cancer. These are not "healthy individuals" but rather individuals with pre-cancerous conditions, and these treatments are performed within strictly controlled, experimental clinical trials.

No, it is not safe or effective to use pembrolizumab as a general, preventative, "vaccine-like" measure in healthy individuals. The potential risks.  Using pembrolizumab (Keytruda) in healthy individuals who do not have cancer, with the goal of stimulating immunity to prevent cancer instead of using cancer vaccines, is currently not an approved or standard medical practice.

While some research is exploring the concept of "immuno-prevention" for high-risk, pre-cancerous conditions, treating healthy individuals with checkpoint inhibitors like pembrolizumab poses significant, often severe, risks to overall health.

 

The Promise and the Limits of Cancer Vaccines: Between Scientific Hope and Biological Reality

I received this information about a Russian cancer vaccine sent to us through my WhatsApp chat group. It was sent to us by Ir. CK Cheong.

Let me quote what he sent to me - or rather to all of us in the WhatsApp. 

“the nightmare scenario for the US is here... Russia, not China, has developed a vaccine for cancer  China is preparing to approve Russia’s groundbreaking cancer vaccine, a development that could disrupt the $2.6 trillion Western oncology market. This vaccine, designed to target and train the immune system to attack cancer cells, represents a major shift from traditional treatments like chemotherapy and radiation. If widely adopted, it could transform how cancer is prevented and treated around the world. The economic implications are massive. Western pharmaceutical companies have long dominated cancer care with treatments generating billions in revenue annually. A safe and effective vaccine from Russia, endorsed and distributed by China, could challenge this dominance, making accessible, cost-effective cancer care available on a global scale and shifting the balance of the industry.”

 https://x.com/NextScience/status/2020145805877977296

Thank you Ir. CK Cheong for the above link. 

Let me explain  what I know about immunotherapy and cancer vaccines.

I shall follow up on this article with two more detailed research  papers  on the same subject - one I wrote on my own, the other together with a cancer immunologist. This would be of great interest to doctors and cancer patients alike if there are other options than the traditional chemotherapy. 

Let me deal with this one first. 

In recent weeks, a message circulating on social media and WhatsApp groups has generated considerable excitement. It claims that Russia has developed a groundbreaking “cancer vaccine” that could potentially disrupt the global oncology industry and even threaten the dominance of Western pharmaceutical companies. According to these reports, China is preparing to approve this vaccine, and if successful, it could transform cancer treatment worldwide by replacing conventional modalities such as chemotherapy and radiotherapy with a single, powerful immunological solution.

At first glance, such claims are understandably captivating. Cancer remains one of humanity’s greatest medical challenges, and any genuine breakthrough naturally inspires hope. However, a careful scientific analysis reveals that the reality is far more remote  and considerably less sensational, than the headlines suggest.

 It may be possible to train the immune system to recognize and attack cancer cells. This approach, known as immunotherapy, is a validated and active area of global cancer research. Russian researchers are currently developing a personalized mRNA-based therapeutic vaccine, which they claim could theoretically be adapted for many types of cancer. However, it is not a "universal" one-size-fits-all shot. While early pre-clinical animal trials showed promising results such as a 60–80% reduction in tumor size since human clinical trials are still in early stages or just beginning. The Russian claim refers to an experimental, personalized mRNA-based vaccine named Enteromix (or similar, details are limited) that is currently in early-stage clinical trials. The vaccine is designed to be personalized, using a patient's unique tumor profile (neoantigens) to create a tailored mRNA sequence that instructs the body's cells to produce proteins that the immune system will recognize as a threat and attack. This is a promising approach in personalized medicine. Russian officials have reported promising results from preclinical studies and early Phase 1 human trials, including significant tumor size reduction and a 100% immune response in some participants, with no serious side effects. Let me explain in technical details how it may work: The vaccine is therapeutic (designed to treat existing tumors) rather than preventive (designed to stop cancer before it starts). Its mechanism is based on the following process: 

 

1.             Tumor Passport Creation: Doctors extract a sample of a patient's tumor and use Artificial Intelligence (AI) to analyze its unique genetic profile.

 

2.             Neoantigen Identification: The AI identifies neoantigens, specific proteins or mutations found only on the cancer cells and not on healthy tissue.

 

3.             mRNA Synthesis: In about a week, scientists synthesize a custom mRNA sequence that carries the "blueprints" for these neoantigens.

 

4.             Immune Instruction: Once injected (typically via lipid nanoparticles), the mRNA instructs the patient’s own cells to produce these cancer-specific proteins.

 

5.             Targeted Attack: The immune system (specifically T-cells) recognizes these produced proteins as foreign threats and "learns" to hunt and destroy any original cancer cells that display them.

 

Current Development Status Target Cancers: Initial human trials, which began or are slated for late 2024 to 2025, focus on melanoma and small cell lung cancer. 

Technology Name: 

Some reports refer to a specific platform called Enteromix, while others highlight the broader mRNA work by the Gamaleya National Research Center (the developers of the Sputnik V COVID-19 vaccine). 

The Russian government has announced that once approved, the vaccine will be provided free of charge to Russian citizens under the national healthcare system. 

Let me explain the caution. International experts emphasize that while the tech is groundbreaking, the "100% success" claims reported by some state media are based on very small-scale or pre-clinical data and have not yet been verified through large-scale, peer-reviewed human trials. 

 

There are  other cancer vaccines too not just the Russian one currently in development, such as those from Moderna or BioNTech? However, as far as I know international medical experts emphasize that these are early-stage results based on small sample sizes. The claims of "100% success" or being "ready for use" are considered exaggerated by the global scientific community, which requires larger, independent, peer-reviewed Phase 2 and Phase 3 clinical trials to confirm safety and effectiveness before any wide-scale approval. 

The Promise and the Limits of Cancer Vaccines: Between Scientific Hope and Biological Reality

Immunotherapy: A Real and Rapidly Advancing Field

The core scientific principle behind these claims is not fiction. It is rooted in a legitimate and rapidly expanding discipline known as cancer immunotherapy, an approach that seeks to train the body’s own immune system to recognize and destroy malignant cells.

Unlike traditional treatments that directly target tumors with drugs or radiation, immunotherapy works indirectly by enhancing immune surveillance, particularly through T-cells. This concept has already yielded successful therapies, including immune checkpoint inhibitors and CAR-T cell therapy, which have revolutionized the management of certain cancers.

The Russian initiative belongs to this same scientific lineage.

The Russian mRNA Vaccine: What Is Actually Being Developed?

Russian researchers, particularly those associated with the Gamaleya National Research Center (the institute behind the Sputnik V COVID-19 vaccine), are developing an experimental, personalized mRNA-based therapeutic cancer vaccine. Some reports refer to the platform as Enteromix, though technical details remain limited and largely unpublished in peer-reviewed international journals.

Importantly, this is not a universal cancer vaccine. It is not designed to prevent cancer in healthy individuals, nor is it a one-size-fits-all cure. Rather, it is a personalized therapeutic vaccine, tailored specifically to each patient’s tumor.

How Such a Vaccine May Work (In Theory) Here are two links for the diagrams

National Cancer Institute – Cancer Vaccines Explained

https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-vaccines

Or even more refined:

A visual illustration of this process is available at the U.S. National Cancer Institute website:

https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-vaccines

The proposed mechanism is scientifically elegant and consistent with current research trends:

Tumor Profiling
A biopsy of the patient’s tumor is genetically sequenced, often with the aid of artificial intelligence.

 Neoantigen Discovery

Unique cancer-specific mutations (neoantigens) are identified, molecular signatures absent in normal cells.

Custom mRNA Design
Scientists synthesize a bespoke mRNA sequence encoding these neoantigens.

Immune Training
The mRNA is delivered into the body using lipid nanoparticles, instructing the patient’s own cells to produce these tumor antigens.

Targeted Immune Attack
T-cells are activated and trained to recognize and destroy cancer cells displaying those antigens.

In essence, the body becomes its own personalized cancer-fighting factory.

Current Evidence: Promising, but Preliminary

According to Russian sources, early pre-clinical studies in animals have demonstrated tumor reductions of up to 60–80%. Small Phase 1 human trials, mainly involving melanoma and small-cell lung cancer, have reportedly shown strong immune activation with minimal side effects.

However, from a scientific standpoint, these results remain exploratory rather than definitive. Phase 1 trials are designed primarily to assess safety, not effectiveness. Claims of “100% success” or “complete cures” are based on very small samples and lack independent international verification.

Without large-scale, randomized Phase 2 and Phase 3 trials published in reputable journals, such claims cannot be regarded as established medical evidence.

 Not a Russian Monopoly: A Global Scientific Effort

It is also crucial to recognize that Russia is not alone in this field. Similar personalized mRNA cancer vaccines are under development by major biotechnology companies, including Moderna and BioNTech. These programs follow nearly identical scientific principles and are likewise in early or mid-stage clinical trials.

Thus, what we are witnessing is not a geopolitical revolution in medicine, but rather a global convergence of scientific innovation driven by advances in genomics, immunology, and artificial intelligence.

 Scientific Hope Versus Biological Reality

The scientific foundations of cancer immunotherapy are solid and inspiring. There is no doubt that personalized vaccines will play an increasingly important role in oncology in the coming decades.

Yet it is equally important to remain realistic.

Cancer is not a single disease, but a vast family of genetically unstable, adaptive biological processes. Tumors evolve, mutate, and evade immune detection. What works spectacularly in one patient may fail entirely in another. The immune system itself is constrained by tolerance mechanisms designed to prevent autoimmunity.

From a broader biological and philosophical perspective, it may also be argued that complete freedom from disease is neither biologically nor existentially consistent with human life. Aging, degeneration, and mortality are deeply embedded in the fabric of living systems. Nature appears to prioritize reproduction, variation, and renewal over indefinite survival.

In that sense, medicine may continue to delay death, reduce suffering, and improve quality of life, but not abolish mortality itself.

My feeling is the Russian mRNA cancer vaccine represents a promising scientific experiment, not a proven cure. Its underlying principles are shared by leading research programs worldwide, and its early results, while encouraging, remain far from conclusive.

The true value of this development lies not in sensational headlines or economic speculation, but in its contribution to a growing body of knowledge that may one day transform cancer into a manageable, chronic condition rather than a fatal diagnosis.

Until then, cautious optimism, guided by rigorous science rather than political or commercial enthusiasm, remains the most intellectually honest stance.

To understand how a personalized cancer vaccine may work, it is helpful to imagine the immune system as a highly trained security force whose main problem is not weakness, but mis-identification. Cancer cells originate from our own tissues, so they often appear “normal” and escape immune detection.

The purpose of a cancer vaccine is therefore not to kill cancer directly, but to teach the immune system what the enemy looks like.

Step 1: Studying the Enemy (Tumor Profiling)

A small sample of the patient’s tumor is first removed through biopsy or surgery. This sample contains millions of cancer cells, each carrying genetic mutations that differ from normal cells.

Using advanced genetic sequencing (often assisted by artificial intelligence), scientists analyze these cancer cells in great detail to identify their unique molecular features.

Step 2: Finding the Cancer’s Fingerprints (Neoantigens)

Among all these mutations, researchers look for neoantigens,  abnormal proteins that exist only on cancer cells and not on healthy tissues.

These neoantigens act like fingerprints or facial features of the cancer. They are the most reliable markers that allow the immune system to distinguish malignant cells from normal ones.

Step 3: Writing the Immune “Instruction Manual” (mRNA Design)

Once the neoantigens are identified, scientists design a customized strand of messenger RNA (mRNA) that contains the genetic instructions for producing those exact cancer-specific proteins.

This mRNA is essentially a biological message that says:
“Here is what the cancer looks like. Learn this.”

Step 4: Teaching the Body (mRNA Injection)

The mRNA is injected into the patient, usually enclosed within microscopic lipid particles that protect it and help it enter cells.

Inside the body, normal cells temporarily read this mRNA and produce harmless copies of the cancer-specific proteins.

Importantly, no cancer is created — only the signature proteins of cancer are displayed.

Step 5: Immune Training (T-cell Activation)

The immune system now sees these abnormal proteins and recognizes them as foreign.

This activates specialized immune cells, especially T-lymphocytes, which begin to memorize these cancer signatures.

In effect, the immune system undergoes a form of vaccination training, similar to how it learns to recognize viruses.

Step 6: The Targeted Attack

Once trained, these T-cells circulate throughout the body searching for any real cancer cells displaying the same neoantigens.

When found, they bind to them and destroy them through immune mechanisms.

Thus, the immune system becomes a precision-guided internal weapon, capable of seeking out and eliminating cancer cells while sparing healthy tissues.

 

Why This Approach Is So Powerful (In Theory)

This method has three major advantages:

1.  Extreme specificity

Only cancer cells are targeted, minimizing damage to normal organs.

2. Personalization

Each vaccine is custom-built for each patient’s tumor.

3. Biological amplification

Once trained, the immune system can continue working long after the injection. In principle, this is one of the most intelligent and elegant strategies ever conceived in oncology.

 

Why It Still Faces Major Limitations

Despite its beauty, several biological challenges remain:

 Cancer mutates rapidly and may change its “appearance.”

Some tumours suppress immune activity.

Not all cancers present strong neoantigens.

Immune exhaustion may occur in advanced disease.

This is why to my personal understanding,  such vaccines work brilliantly in some patients and poorly in others, and why universal success remains unlikely.

A Deeper Reflection

In philosophical terms - a spiritual area I am always interested in - not just in medicine and science only -  this technology to me does not “defeat nature.”
It merely cooperates with nature, by enhancing the body’s existing defensive intelligence.

Medicine here is not creating immortality, but borrowing time from entropy,  delaying decline, reducing suffering, and improving quality of life, while remaining subject to the deeper biological laws of aging and mortality.

Having written and explained all that, my feeling is, I think the scientific principle is sound and part of a global effort in immunotherapy research, but the specific Russian vaccine's claims require further independent validation through rigorous, large-scale clinical trials. 

Let me conclude by saying I think we cannot be too confident about this Russian vaccine or any other vaccines against cancer because Nature too has its purpose to fight back in that we cannot remain here free from any disease, including cancer for us to continue to live here in this world forever. 

See my explanation here:

https://scientificlogic.blogspot.com/2026/02/why-must-it-be-necessary-for-us-to-age.html?m=1  

Some references (for further reading)

1.  Sahin U., Türeci Ö. Personalized vaccines for cancer immunotherapy. Science, 2018.

2. Waldman A.D. et al. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology, 2020.

3. Ott P.A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017.

4. Moderna Oncology Pipeline – mRNA Cancer Vaccines.

BioNTech Individualized Neoantigen Therapies (iNeST Program).